PDCD1 and non-small cell lung carcinoma: The predictive advantage was also demonstrated in two independent studies that analyzed fecal samples of NSCLC (n = 70), NSCLC (n = 14), and gastric cancer (n = 24) patients, confirming that patients with Ruminococcaceae enrichment had a robust clinical response to PD-1 blockade (Figure 2; Table 1).77